CN101411749B - Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis - Google Patents
Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis Download PDFInfo
- Publication number
- CN101411749B CN101411749B CN2008102259636A CN200810225963A CN101411749B CN 101411749 B CN101411749 B CN 101411749B CN 2008102259636 A CN2008102259636 A CN 2008102259636A CN 200810225963 A CN200810225963 A CN 200810225963A CN 101411749 B CN101411749 B CN 101411749B
- Authority
- CN
- China
- Prior art keywords
- group
- sinusitis
- allergic rhinitis
- preparation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating sinusitis and allergic rhinitis. The traditional Chinese medicine composition for treating the sinusitis and the allergic rhinitis comprises various bulk drugs in portion by weight: 1 to 30 portions of lily magnolia, 1 to 25 portions of Chinese ephedra and 2 to 30 portions of radix sophorae falvescentis. The preparation can be nasal drop, a spraying agent, aerosol, salve or cream.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of sinusitis and allergic rhinitis, belong to technical field of Chinese medicines.
Background technology
Sickness rate in China's sinusitis and allergic rhinitis is very high, accounts for the first place of outpatient service and inpatient at its sickness rate of department of otorhinolaryngology, up to 10%～15%.And, clinically lack effective treatment by Chinese herbs medicine along with the aggravation of polluting always.
Sinusitis is the suppurative inflammation of nasal sinuses mucosa, is more common in after flu, the acute rhinitis.In addition, allergic constitution and systemic disease such as anemia, influenza etc. also can cause the generation of primary disease, contiguous focal infection, amygdala hypertrophy, adenoid vegetation, some grind one's teeth in sleep root infection and nose department flesh wound, foreign body penetrates nasal sinuses, carriage improper (as vertical diving) during swimming, sewage enters to wait in the hole and directly injures nasal sinuses, all can cause infection.Also just like diaphragm bending in the nose, nose diseasess such as middle nasal concha hypertrophy, nasal polyp, tumor hinder nasal sinuses ventilation drain also can cause primary disease.Chronic sinusitis is many not to be obtained due to the suitable treatment because of acute sinusitis shows effect repeatedly.Reveal any symptoms: 1, nasal secretion increases: this is the sinusitis common sympton, can be one-sided property or both sides property.Nasal secretions flows out to anterior nares, or flows into nasopharynx part backward, patient Chang Suwei " abundant expectoration ".Secretions belongs to mucus purulence or pure purulence, sometimes the conscious foul smelling of patient.2, nasal obstruction: obstruction is all felt in one or both sides, and rise more very morning.Blocking weight decides on the change of nasal secretion number, sinusitis scope and weather.It is also insensitive that back olfactory sensation takes place nasal obstruction.Suffer from the acute sinusitis person, nasal obstruction more so.3, headache and local pain: headache also be the sinusitis common sympton, and its occurrence cause is due to the thick and ischesis pressuring nerve of the interior mucosal swelling of hole.
Allergic rhinitis is the rhinitis that certain material allergy is caused owing to body, and can cause that a series of allergic conditions occur, mostly be paroxysmal rhinocnesmus, continuous sneeze, flowing water sample or thin mucoid tears, and nasal obstruction, hyposmia, soft palate, ear, eye, bottleneck throat gargalesthesia and headache etc. also can be arranged.
Summary of the invention
Technical problem to be solved by this invention is, a kind of Chinese medicine composition for the treatment of the determined curative effect of sinusitis and allergic rhinitis is provided.
For solving the problems of the technologies described above, the invention discloses a kind of Chinese medicine composition for the treatment of sinusitis and allergic rhinitis, it is characterized in that the ratio of weight and number of crude drug is: Flos Magnoliae 1-30 part, Herba Ephedrae 1-25 part, Radix Sophorae Flavescentis 2-30 part.
The Chinese medicine composition of described treatment sinusitis and allergic rhinitis is characterized in that, the ratio of weight and number of crude drug is: Flos Magnoliae 4-15 part, Herba Ephedrae 13-18 part, Radix Sophorae Flavescentis 9-21 part.
The Chinese medicine composition of described treatment sinusitis and allergic rhinitis is characterized in that, the ratio of weight and number of crude drug is: Flos Magnoliae 5-8 part, Herba Ephedrae 14-16 part, Radix Sophorae Flavescentis 17-20 part.
The Chinese medicine composition of described treatment sinusitis and allergic rhinitis is characterized in that made preparation can be nasal drop, spray, aerosol, ointment or cream.
Described Chinese medicine composition, the application in the medicine of preparation treatment sinusitis and allergic rhinitis.
The invention has the advantages that: easy to use, evident in efficacy, its employed raw material is the Chinese medicine that the Pharmacopoeia of the People's Republic of China records, and the dosage of use all in scope safely and effectively, has no side effect, and is a kind of very competitive modern Chinese medicine.
The specific embodiment
Pharmacodynamics test cures mainly the vivo and vitro antibacterial action of having observed this product according to its function, to the effect of nosal inflammation model, to the microcirculation of mouse auricle influence, reaches analgesia, antiinflammatory action.The result shows that this product has stronger inhibitory action to beta hemolytic streptococcus, hemophilus influenza, streptococcus pneumoniae, staphylococcus aureus, staphylococcus epidermidis; Pseudomonas aeruginosa, Candida albicans there is bacteriostasis; There is the prolongation effect in life-span to intraperitoneal injection pseudomonas aeruginosa and beta hemolytic streptococcus infecting mouse; Xylol induced mice acute rhinitis has therapeutical effect; Can improve the Mice Auricle microcirculation, function of promoting blood circulation to disperse blood clots is arranged; And have the analgesia and antiinflammatory action.
In the pharmacodynamics test preparation of the present invention also with BIKANG PENWUJI (ratio of weight and number of Radix Sophorae Tonkinensis, Flos Magnoliae, Herba Ephedrae is that the proportioning of the 5:10:4 makes) test of comparing, the result shows that the effect of preparation of the present invention is better than BIKANG PENWUJI.
The pharmacodynamics test method is as follows:
1, trial drug;
Preparation of the present invention, every bottled 10ml.
2, laboratory animal:
The ICR mice, body weight 18～22g, the quality certification number: the moving word 08-24 of doctor; 08-004 number.The SD rat, body weight 180～220g, the quality certification number: the moving word 08-25 of doctor; 08-24 number; Provide by Traditional Chinese Medicine Research Institute, Shanxi Province and Shanghai Communications University, Xi'an medical college Experimental Animal Center.
3, test method and result
(1) to the inhibition and the killing action of seven kinds of upper respiratory tract common bacterias
1. medicinal liquid is prepared
Get said preparation 50ml, water proof boils 30min, adds to 50ml with physiological saline solution, gets the 0.1ml medicinal liquid and adds in the aseptic meat soup of 1ml, cultivates 18～24h for 37 ℃, and the negative rearmounted refrigerator of sterility test is standby.
2. test strain
Staphylococcus aureus ATCC 25923 strains
Pseudomonas aeruginosa ATCC 27853 strains
Staphylococcus epidermidis 26069 strains
Beta hemolytic streptococcus 10034 strains
Streptococcus pneumoniae 31001 strains
Hemophilus influenza 28635 strains
Candida albicans 10131 strains
Above reference culture lyophilizing bacterial strain is identified institute Chinese antibacterial preservation center available from Chinese Academy of Medical Sciences's Beijing pharmaceutical biological product, in February, 2007 recovery, and the test forward pass is for standby.
3. test organisms liquid preparation
Staphylococcus aureus, staphylococcus epidermidis, pseudomonas aeruginosa, Candida albicans are inoculated in MH meat soup, put 37 ℃ of common incubators, 18h cultivation; Hemophilus influenza, group B streptococcus, streptococcus pneumoniae are inoculated in blood plate, put 5%CO
2Incubator, it is 1.5 * 10 that Maxwell standard opacity tube is adjusted bacterial concentration
8CFu/ml, standby behind the redilution.
4. test method
Adopt the test tube doubling dilution to measure MIC, dull and stereotyped transferred species method is measured MBC
A measures MIC, the MBC of staphylococcus aureus, staphylococcus epidermidis, pseudomonas aeruginosa
Said preparation is carried out 2ml/2ml continuous 2 times gradient dilutions by 50% (W/V) for starting point with MH meat soup, and adding concentration successively is 10
6The test organisms liquid 0.05ml of cFu/ml.Set up the contrast of antibacterial and culture medium simultaneously.Put 37 ℃ of common incubators, 18h cultivation, observe minimum inhibitory concentration (MIC), the culture 0.1ml that will not see each pipe of bacterial growth more successively joins respectively in the MH culture medium, put 37 ℃ of common incubators, 18h cultivates, and clump count is minimal bactericidal concentration (MBC) less than contained minimum drug level in 5 the flat board on the flat board.
B measures MIC, the MBC of beta hemolytic streptococcus, streptococcus pneumoniae, hemophilus influenza
With the MH meat soup of said preparation with 5% hyclone, carry out the continuous 2 times of gradient dilutions of 2ml/2ml by 50% (W/V) for starting point, adding concentration successively is 10
6The test organisms liquid 0.05ml of cFu/ml.Set up antibacterial and culture medium negative control simultaneously.Put 5%CO
235 ℃ of incubators, 24h are cultivated, and observe minimum inhibitory concentration (MIC), will not have in the bacterial growth test tube culture 0.1ml successively transferred species arrive blood plate, clump count is minimal bactericidal concentration (MBC) less than contained minimum drug level in 5 the flat board on the flat board.
C measures the oidiomycetic MIC of white, MBC
With said preparation with husky protect Ruo Shi (Sabourraud, SD) meat soup carries out the continuous 2 times of gradient dilutions of 2ml/2ml by 50% (W/V) for starting point, adding concentration successively is 10
6The test organisms liquid 0.05ml of cFu/ml.Set up antibacterial and culture medium negative control simultaneously.Put 37 ℃ of common incubators, 24h cultivation, observe minimum inhibitory concentration (MIC), transferred species is to the husky Ruo Shi of guarantor flat board successively will not have in the bacterial growth test tube culture 0.1ml, and clump count is minimal bactericidal concentration (MBC) less than contained minimum drug level in 5 the flat board on the flat board.
5. result
The MIC and the MBC of table 1 pair 7 kinds of reference cultures
| Bacterial strain | Bacterium number | MIC (extension rate), concentration (crude drug g/ml) | MBC (extension rate), concentration (crude drug g/ml) |
| Staphylococcus aureus | The ATCC25923 strain | 1：4 0.805 | >1：2 |
| Pseudomonas aeruginosa | The ATCC27853 strain | 1：2 1.61 | >1：2 |
| Staphylococcus epidermidis | 26069 strains | 1：4 0.805 | >1：2 |
| Beta hemolytic streptococcus | 10034 strains | 1：64 0.05 | 1：8 0.40 |
| Streptococcus pneumoniae | 31001 strains | 1：8 0.403 | >1：2 |
| Hemophilus influenza | 28635 strains | 1：8 0.403 | 1：2 1.60 |
| Candida albicans | 10131 strains | 1：2 1.61 | >1：2 |
As shown in Table 1, said preparation is stronger to the effect of hemophilus influenza and beta hemolytic streptococcus, MIC is between 1:8～1:64 (crude drug concentration 0.403g/ml, 0.05g/ml), MBC is 1:2～1:8 (crude drug concentration 1.61g/ml, 0.403g/ml), effect to staphylococcus aureus, staphylococcus epidermidis and streptococcus pneumoniae is taken second place, MIC is between 1:4～1:8, MBC is〉1:2, poor slightly to pseudomonas aeruginosa, Candida albicans effect, MIC is 1:2, and MBC is〉1:2.The result shows that said preparation can suppress and deactivation respiratory tract common pathogen effectively.
(2) antibacterial tests in the body
1. preparation, injection and the counting of pseudomonas aeruginosa and beta hemolytic streptococcus bacterium liquid
Pseudomonas aeruginosa MH agar culture medium, beta hemolytic streptococcus is used blood plate, respectively goes down to posterity 1 time, gets new fresh thalli and is used for test.Get pseudomonas aeruginosa bacterium liquid MH meat soup, beta hemolytic streptococcus is with the MH cultured solution of broth of 5% hyclone, after cultivating 24h in 37 ℃ of incubators, 1:1 mixes, dilute with sterile saline, reuse 721 type spectrophotometers transfer the concentration of pseudomonas aeruginosa and beta hemolytic streptococcus mixed bacteria liquid to make OD value to 0.42 in 550nm wavelength place colorimetric, take out part bacterium liquid and do count of bacteria.Every mouse peritoneal injection bacterium liquid 0.5ml.Every injected in mice pseudomonas aeruginosa and beta hemolytic streptococcus amount are about 4 * 107, are the minimal lethal dose that trial test confirms.
2. said preparation is to the protective effect of lumbar injection pseudomonas aeruginosa and beta hemolytic streptococcus mice
Mice is divided into 6 groups at random, and 12 every group, male and female half and half, i.e. model control group (lumbar injection equal-volume physiological saline solution); Cefradine Capsules group (oral cefradine capsule 6.67g/kg is equivalent to 10 times of the clinical plan consumption of people); BIKANG PENWUJI 0.134ml/kg is equivalent to 20 times of the clinical plan consumption of people; Large, medium and small 3 the dosage groups of preparation of the present invention, intraperitoneal injection, dosage are respectively 0.334ml/kg, 0.167ml/kg, 0.084ml/kg.6h after the first administration, the pseudomonas aeruginosa of lumbar injection minimum lethal dose and beta hemolytic streptococcus, 4h after the modeling, each organizes administration or physiological saline solution, every day 2 times, 3d continuously.Observed for 1 week continuously, every 3h observed 1 time in the 1st day, observed every day afterwards 2 times.Statistical procedures adopts SPSS software to carry out Chi-Square Tests.(table 2)
The interior protective effect to pseudomonas aeruginosa and beta hemolytic streptococcus infection of table 2 body (X ± S)
| Group | Dosage | Number of animals (only) | Survival number (only) | Death toll (only) | Mortality rate (%) |
| Model control group | — | 12 | 1 | 11 | 91.7 |
| The cefradine Capsules group | 6.67g/kg | 12 | 12 | 0 | 0 ** |
| Heavy dose of | 0.334ml/kg | 12 | 12 | 0 | 0 ** |
| Middle dosage | 0.167ml/kg | 12 | 12 | 0 | 0 ** |
| Low dose of | 0.084ml/kg | 12 | 12 | 0 | 0 ** |
| BIKANG PENWUJI | 0.134ml/kg | 12 | 12 | 0 | 0 ** |
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01
By table 20-2 as can be known, mortality rate reaches 91.7% in injection pseudomonas aeruginosa and the beta hemolytic streptococcus mice 7d.The success of infecting mouse model is described.Cefradine capsule and this product and BIKANG PENWUJI mortality rate are 0.The result shows that said preparation has inhibitory action to pseudomonas aeruginosa and beta hemolytic streptococcus.
(3) to the effect of nosal inflammation model
Get 70 of mices, male and female half and half, body weight 20 ± 2g is divided into 7 groups at random, 6 groups of mice nasal cavity melted paraxylenes wherein, each 0.01ml, 2 times/d, 3d makes mice present the acute rhinitis symptom continuously; Other 1 group drips normal saline as the blank group.After the 3d modeling, in administration on the 4th, blank group and model control group are dripped normal saline, positive controls is dripped DITONG BIYAN SHUI 0.053ml/kg (be equivalent to be grown up consumption 20 times), BIKANG PENWUJI 0.134ml/kg (be equivalent to be grown up consumption 20 times), preparation of the present invention large, medium and small 3 dosage group 0.334ml/kg, 0.167ml/kg, 0.084ml/kg collunarium.Every day 1 time, successive administration 4d.1h takes off neck execution after all animal last administrations, cuts nasal tissue, uses formalin fixed, specimens paraffin embedding slices, and HE dyeing, microscopically is observed and is respectively organized pathological change.Statistical procedures adopts the X 2 test computer to carry out X 2 test.(table 3).
The effect of table 3 pair mice nosal inflammation model (X ± S, n=10)
Annotate: compare with the blank group
*P＜0.05,
*P＜0.01
By table 20-3 as can be known, after the modeling, the visible mice nose of naked eyes redness, the wing of nose thickens, and vibrissa comes off.Model control group has 1 example to recover naturally, and the large, medium and small dosage group of DITONG BIYAN SHUI, BIKANG PENWUJI and said preparation compares with model control group, and recovery rate is significantly improved.As seen histopathologic slide causes scorching mice tela submucosa vasodilation hyperemia in microscopically, the surrounding tissue edema, and cell infiltration, comes off at the mucosal necrosis that has.The result shows, with model control group relatively, the acute rhinitis model due to the big or middle dosage group of DITONG BIYAN SHUI and the said preparation xylol can obviously alleviate cell infiltration and inflammatory necrosis, promote chmice acute rhinitis recovery rate, illustrate that said preparation has therapeutical effect to acute rhinitis.
(4) microcirculation of mouse auricle is influenced
60 of healthy ICR mices, body weight 20 ± 2g, be divided into 6 groups at random, every group 10, ♀ ♂ half and half, with mice with 1% pentobarbital sodium 0.05ml/10g intraperitoneal injection of anesthesia (strict sterilization), ventrad be fixed on the mice observation platform down, make auricle open and flat in the ear holder, and selected somewhere, boundary picric acid labelling in one's ear, in the ear holder, drip a little cedar oil with the auricle surface, observation platform is placed on the micro-object stage of the biological microcirculation microscope of BI-2000 medical image analysis system three orders, regulate the suitable brightness in floodlight source, under 50 times of mirrors, observe, start microcirculation software, adjust the mirror downward view, make by video camera and be transferred to clear picture on the computer screen, near selected a certain border gauge point, the vascularity sketch that draws (finding former survey vascular site when observing in order to next time) is measured its blood capillary opening amount, blood flow rate (μ m/s), blood vessel input bore (μ m) and blood vessel output bore (μ m).The 1st group for the normal control group is coated with water for injection 0.05ml/10g, and the 2nd group is coated with DIEDA WANHUAYOU 0.05ml/10g, the 3rd～5 group of 0.334ml/kg, 0.167ml/kg, 0.084ml/kg respectively, the 6th group of injection BIKANG PENWUJI 0.134ml/kg.1h behind the coating measures vessel open amount, blood flow rate, blood vessel input bore and the blood vessel at the former position of mice and exports bore, deducts the preceding analog value of administration and is vessel open amount changing value, blood flow rate changing value, blood vessel input and output bore changing value.(table 4, table 5 contrast between group, the t check)
The influence of table 4 pair Mice Auricle blood capillary opening amount and blood flow rate (X ± S, n=10)
Annotate: contrast with the normal control group
*P＜0.05,
*P＜0.01
The influence of table 5 pair Mice Auricle blood capillary input caliber, output caliber (X ± S, n=10)
Annotate: contrast with the normal control group
*P＜0.05,
*P＜0.01
By table 4, table 5 as can be known, the big or middle dosage of said preparation can make the Mice Auricle capillary blood flow speed up, and blood vessel input bore increases; Heavy dose can make Mice Auricle vessel open quantity increase, and the output bore increases.
Prompting: this product can be improved the Mice Auricle microcirculation, and function of promoting blood circulation to disperse blood clots is arranged.Effective dose is 0.167ml/kg.
(5) analgesic test (mice tail-flick method)
Get 66 of ICR mices, the male and female dual-purpose, body weight 18g～22g, survey mouse tail point twice of the threshold of pain (50 ± 0.5 ℃ of water-baths are with 2cm in the mouse tail entry) in advance, choose the threshold of pain in 3～10s scope, differ the mice that is no more than 4s twice, height by the sex and the threshold of pain is divided into 6 groups at random, matched group, positive drug group, large, medium and small 3 the dosage groups of said preparation, BIKANG PENWUJI group.The control group mice afterbody is smeared distilled water, volume 0.05ml/10g.Positive group is irritated stomach 0.25% indometacin, volume 0.1ml/10g.Other 3 groups respectively mouse tail smear said preparation 0.334ml/kg, 0.167ml/kg, 0.084ml/kg.BIKANG PENWUJI group 0.134ml/kg.Every day 1 time, successive administration 5d.The positive is organized last administration 1 time, surveys the threshold of pain of 1h and 2h after the last administration, relatively t check (table 6) between organizing with meansigma methods before the administration and the prolongation value after the administration.
As shown in Table 6, said preparation heavy dose 1h after administration can obviously prolong the response time of mice whipping, improves threshold value.
The influence of table 6 pair mice whipping time (X ± S, n=11)
| Group | Dosage | Before the administration (s) | 1h after the administration (s) | 2h after the administration (s) |
| The water matched group | 0.05ml/10g | 5.24±0.82 | 0.73±1.06 | 0.87±1.01 |
| The indometacin group | 25mg/kg | 5.28±0.89 | 2.92±1.84 ** | 1.91±0.98 * |
| Heavy dose of group | 0.334ml/kg | 5.12±0.91 | 1.68±0.93 * | 1.04±1.30 |
| Middle dosage group | 0.167ml/kg | 5.18±0.86 | 1.12±0.90 | 0.96±1.23 |
| Small dose group | 0.084ml/kg | 5.15±0.75 | 0.94±1.50 | 1.19±1.55 |
| BIKANG PENWUJI | 0.134ml/kg | 5.16±0.75 | 1.31±0.80 | 1.04±1.21 |
Annotate: compare with matched group
*P＜0.05,
*P＜0.01
(6) antiinflammatory test
1. xylol causes the influence of mice auricle swelling
Get 66 of healthy ICR mices, the male and female dual-purpose, body weight 18g～22g is divided into 6 groups at random, 11 every group.Be respectively matched group, deionized water 20ml/kg is smeared on the two sides before and after the auris dextra, positive group, acetic acid fluorine fluocinolone acetonide cream 25mg/kg is smeared on the two sides, large, medium and small 3 the dosage group 0.334ml/kg of said preparation, 0.167ml/kg, 0.084ml/kg, BIKANG PENWUJI group 0.134ml/kg are smeared in the two sides before and after the administration group auris dextra.The two sides is coated with the about 20 μ l modelings of dimethylbenzene before and after giving mouse right ear, and left ear is done normal control.Coating immediately after the modeling, behind the 30min, draw neck to put to death mice, cut two ears along the auricle baseline, with diameter be the card punch of 9mm respectively in two ear corresponding sites punchings, scales/electronic balance weighing, left side ear is contrast, with two ear weight differences is the swelling degree, and asks inhibitory rate of intumesce (%), swelling degree suppression ratio=(administration group swelling degree-matched group swelling degree)/matched group swelling degree.Relatively t check (table 7) between group.
The bullate influence of table 7 pair mouse ear (X ± S, n=11)
| Group | Dosage | Left side ear heavy (mg) | Auris dextra heavy (mg) | Swelling degree (mg) | Suppression ratio (%) |
| Matched group | 20ml/kg | 43.82±3.28 | 65.00±5.92 | 23.91±5.45 | — |
| The fluocinonide group | 25mg/kg | 42.82±3.06 | 60.18±4.64 | 17.36±5.22 ** | 27.39％ |
| Heavy dose of group | 0.334ml/kg | 41.72±3.61 | 60.03±6.23 | 18.54±5.80 * | 22.46％ |
| Middle dosage group | 0.167ml/kg | 41.82±3.66 | 64.18±6.97 | 22.36±4.64 | 6.48％ |
| Small dose group | 0.084ml/kg | 41.82±2.79 | 63.91±3.75 | 21.91±2.39 | 8.36％ |
| BIKANG PENWUJI | 0.134ml/kg | 42.67±3.27 | 63.13±6.23 | 20.46±3.27 | 14.47％ |
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01
Table 7 as can be known, it is swollen that the heavy dose of group of said preparation can obviously suppress dimethylbenzene induced mice ear.
2. to the influence of mouse peritoneal capillary permeability
Get 50 of mices, body weight 18～22g is divided into 6 groups at random, and 10 every group,
Half and half.Be respectively matched group-abdominal part and smear deionized water 20ml/kg, positive group-abdominal part is smeared acetic acid fluorine fluocinolone acetonide cream 25mg/kg, administration group-abdominal part is smeared large, medium and small 3 the dosage group 0.334ml/kg of said preparation, 0.167ml/kg, 0.084ml/kg, BIKANG PENWUJI group 0.134ml/kg.Give mouse tail vein injection Yi Wensilan 0.1ml/10g, inject 0.8% glacial acetic acid 0.2ml to mouse peritoneal at once, the while is coating immediately, takes off cervical vertebra behind the 20min and puts to death mice, cuts open the belly with the azovan blue in normal saline washing abdominal cavity, collects washing liquid 6ml.721 spectrophotometer colorimetrics, wavelength 590nm returns to zero with distilled water.In case of collecting the liquid muddiness, then need centrifugal 10min (3000r/min), colorimetric again.According to the OD value, relatively t check (table 8) between group.
The influence of table 8 pair mouse peritoneal capillary permeability (X ± S, n=10)
| Group | Dosage | Number of animals (only) | The OD value | The P value |
| Matched group | 20ml/kg | 10 | 0.192±0.049 | |
| The fluocinonide group | 25mg/kg | 10 | 0.130±0.058 * | P<0.05 |
| Heavy dose of | 0.334ml/kg | 10 | 0.142±0.053 * | P<0.05 |
| Middle dosage | 0.167ml/kg | 10 | 0.150±0.063 | P>0.05 |
| Low dose of | 0.084ml/kg | 10 | 0.170±0.040 | P>0.05 |
| BIKANG PENWUJI | 0.134ml/kg | 10 | 0.182±0.047 | P>0.05 |
Table 8 as can be known, the heavy dose of group of said preparation OD value is starkly lower than matched group, shows the seepage discharge of this product inhibition mouse peritoneal Yi Wensilan, promptly obviously suppresses capillary permeability.
On Carrageenan causes the influence of rat paw edema
Get 48 of rats, be divided into 6 groups at random, 8 every group,
Half and half.Be respectively matched group, foot sole of the foot face is smeared deionized water 10ml/kg, positive group, foot sole of the foot face is smeared acetic acid fluorine fluocinolone acetonide cream 20mg/kg, administration group foot sole of the foot face is smeared large, medium and small 3 the dosage group 0.251ml/kg of said preparation, 0.125ml/kg, 0.063ml/kg, BIKANG PENWUJI group 0.134ml/kg.Cause and survey the right back sufficient sole of the foot of all animals earlier before scorching and enclose (mm) 2 times (twined for 2 weeks with surgical thread at the same position of the right back sufficient sole of the foot, cut, measure the length of surgical thread and enclose) as the sufficient sole of the foot, with 2 times meansigma methodss as normal value.The right back sufficient subcutaneous injection 1% carrageenin 0.1ml/ of all animals, the while is coating immediately, surveys the right sufficient sole of the foot every 1h then and encloses 1 time, survey altogether 6 times, as swelling value (mm), the swelling value deducts and causes the scorching front foot sole of the foot and enclose the swelling degree that is rat, relatively, t checks (table 9) between organizing.
Table 20-6-3 on Carrageenan cause rat paw edema influence (X ± S, n=8)
Annotate: compare with matched group
*P＜0.05
*P＜0.01
As shown in Table 9, fluocinonide obviously reduces the swelling degree (P＜0.05, P＜0.01) of rat at 2～6h, and said preparation obviously reduces the swelling degree (P＜0.05, P＜0.01) of rat at 3～5h, and onset dosage is 0.063ml/kg.
Embodiment one: a kind of pharmaceutical composition for the treatment of sinusitis and allergic rhinitis, the ratio of weight and number of various compositions are 30 parts of Flos Magnoliaes, 25 parts in Herba Ephedrae, 30 parts of Radix Sophorae Flavescentiss.
Case 1: Mrs Wang, 32 years old, heavier sinusitis 6 years, once ate multiple in, Western medicine preparation is all invalid.Cardinal symptom is: it is obstructed to have a stuffy nose, and rhinorrhea is had a headache often, lack of appetite, and hypomnesis is often caught a cold.
Treatment: the spray that uses Chinese medicine of the present invention to make, take effect after 2 days, nose has relaxation, continue to use 6 days, nose energy normal ventilation, the headache symptom obviously alleviates, basically can normally fall asleep night, continues to use to three courses of treatment (7 days is a course of treatment), and appetite is normal, the complete obiteration of headache symptom, night can be normal sleeping as ordinary person, and sinusitis is fully recovered, cures not recur so far, and during also seldom the flu, do not find side effect yet.
Embodiment two: drug regimen composition formula of the present invention can also be by following ratio of weight and number: 1 part of Flos Magnoliae, 1 part in Herba Ephedrae, 2 parts of Radix Sophorae Flavescentiss.
Case 2: Mr. Zhao, 21 years old, light sinusitis 2 years.Cardinal symptom is: it is obstructed to have a stuffy nose, and rhinorrhea is had a headache often, lack of appetite, and hypomnesis is often caught a cold.
Treatment: the spray that uses medicine of the present invention to make, take effect after 1 day, nasal cavity feels relief, idol has nasal mucus to flow out, and continues to use to a course of treatment (7 days is a course of treatment) the headache transference cure, do not have nasal mucus to flow out, appetite increases, and spirit is obviously got better than before, memory also obviously improves than before, after after treatment course of treatment, recovery from illness was not recurred so far, and during also seldom the flu, do not find side effect yet.
Embodiment three: drug regimen composition formula of the present invention can also be by following ratio of weight and number: 6 parts of Flos Magnoliaes, 15 parts in Herba Ephedrae, 18 parts of Radix Sophorae Flavescentiss.
Case 3: Mr. Meng, 47 years old, nearly 20 years of allergic rhinitis, during once repeatedly treatment all do not effect a radical cure.Need medication every day, just can recur in the week after the drug withdrawal, cardinal symptom is: mostly be paroxysmal rhinocnesmus, continuously sneeze, nasal obstruction, headache.
Treatment: the spray that uses medicine of the present invention to make, begin to take effect after half course of treatment, nasal cavity has relaxation, after continuing to use a course of treatment (7 days is a course of treatment), the eupnea of nasal cavity energy, but the nasal obstruction phenomenon is arranged once in a while, continue again to use three courses of treatment, the allergic rhinitis recovery from illness, cure the existing time more than 2 years so far, do not recur, and during also seldom the flu, generation has no side effect.
Embodiment four: drug regimen composition formula of the present invention can also be by following ratio of weight and number: 30 parts of Flos Magnoliaes, 2 parts in Herba Ephedrae, 30 parts of Radix Sophorae Flavescentiss.
Case 4: CHENNU scholar, 32 years old, heavier sinusitis 6 years.Cardinal symptom is: it is obstructed to have a stuffy nose, and rhinorrhea is had a headache often, lack of appetite, and hypomnesis is often caught a cold.
Treatment: the spray that uses medicine of the present invention to make, take effect after 2 days, nose has relaxation, continue to use 6 days, nose energy normal ventilation, the headache symptom obviously alleviates, basically can normally fall asleep night, continues to use to 3 courses of treatment (7 days is a course of treatment), and appetite is normal, the complete obiteration of headache symptom, night can be normal sleeping as ordinary person, and sinusitis is fully recovered, cures not recur so far, and during also seldom the flu, do not find side effect yet.
Embodiment five: drug regimen composition formula of the present invention can also be by following ratio of weight and number: 4 parts of Flos Magnoliaes, 18 parts in Herba Ephedrae, 9 parts of Radix Sophorae Flavescentiss.
Case 5: Mr. Qi, 21 years old, light sinusitis 2 years, once ate multiple in, Western medicine preparation all can't effect a radical cure.Cardinal symptom is: it is obstructed to have a stuffy nose, and rhinorrhea is had a headache often, lack of appetite, and hypomnesis is often caught a cold.
Treatment: the spray that uses medicine of the present invention to make, take effect after 1 day, nasal cavity feels relief, idol has nasal mucus to flow out, and continues to use to 1 course of treatment (7 days is a course of treatment) the headache transference cure, do not have nasal mucus to flow out, appetite increases, and spirit is obviously got better than before, memory also obviously improves than before, after after treatment course of treatment, recovery from illness was not recurred so far, and during also seldom the flu, do not find side effect yet.
Claims (5)
1. a Chinese medicine composition for the treatment of sinusitis and allergic rhinitis is characterized in that, the ratio of weight and number of crude drug is: Flos Magnoliae 1-30 part, Herba Ephedrae 1-25 part, Radix Sophorae Flavescentis 2-30 part.
2. Chinese medicine composition according to claim 1 is characterized in that, the ratio of weight and number of crude drug is: Flos Magnoliae 4-15 part, Herba Ephedrae 13-18 part, Radix Sophorae Flavescentis 9-21 part.
3. Chinese medicine composition according to claim 2 is characterized in that, the ratio of weight and number of crude drug is: Flos Magnoliae 5-8 part, Herba Ephedrae 14-16 part, Radix Sophorae Flavescentis 17-20 part.
4. according to each described Chinese medicine composition among the claim 1-3, it is characterized in that made preparation can be nasal drop, spray, aerosol, ointment or cream.
5. each described Chinese medicine composition among the claim 1-4, the application in the medicine of preparation treatment sinusitis and allergic rhinitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102259636A CN101411749B (en) | 2008-11-07 | 2008-11-07 | Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102259636A CN101411749B (en) | 2008-11-07 | 2008-11-07 | Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101411749A CN101411749A (en) | 2009-04-22 |
| CN101411749B true CN101411749B (en) | 2011-06-08 |
Family
ID=40592628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102259636A Expired - Fee Related CN101411749B (en) | 2008-11-07 | 2008-11-07 | Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101411749B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265966A (en) * | 2016-10-21 | 2017-01-04 | 张有强 | A kind of Chinese medicine treating sinusitis, allergic rhinitis, nasal conchae hypertrophy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589852A (en) * | 2003-08-28 | 2005-03-09 | 昆明滇虹药业有限公司 | External use nose drop agent for treating common cold and its preparation method |
| CN1785235A (en) * | 2004-12-06 | 2006-06-14 | 张贵君 | Bikang spray for treating nose disease |
-
2008
- 2008-11-07 CN CN2008102259636A patent/CN101411749B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589852A (en) * | 2003-08-28 | 2005-03-09 | 昆明滇虹药业有限公司 | External use nose drop agent for treating common cold and its preparation method |
| CN1785235A (en) * | 2004-12-06 | 2006-06-14 | 张贵君 | Bikang spray for treating nose disease |
Non-Patent Citations (1)
| Title |
|---|
| 张廷模，陈先男.苦参 山豆根.《中药学》.2001,95－96，112. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101411749A (en) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104488986A (en) | Traditional Chinese medicine sterilizing liquid for clinical laboratory | |
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN104288356B (en) | Treat traditional Chinese medicine infusion solution of mastitis for milk cows and preparation method thereof | |
| CN108685996A (en) | It is a kind of to be used to prevent external natural pharmaceutical composition of acne and preparation method thereof | |
| CN105709081B (en) | Pharmaceutical composition for treating infectious rhinitis of chicken, application and feed thereof | |
| CN101181540B (en) | Application of pharmaceutical composition in the preparation of medicine for prostatitis resistance | |
| CN102600195A (en) | Composite transdermal linimentum for pets as well as preparation method and application of composite transdermal linimentum | |
| CN109010529A (en) | A kind of Traditional Chinese medicine bacteriostatic gelling agent for vagina nursing | |
| CN101411749B (en) | Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis | |
| CN102335185A (en) | Purpose of icariin in preparation of medicines used for treating bronchial asthma | |
| CN102302505B (en) | Medicinal composition for treating pelvic inflammatory disease and application thereof | |
| CN102743432B (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN102485239B (en) | Chinese herbal composition used for treating gynecological inflammation | |
| CN102755563B (en) | Traditional Chinese medicine composition for treating chronic prostatitis and preparation method thereof | |
| CN103893300B (en) | A kind of Chinese medicine composition treating cow endometritis and preparation method and application | |
| CN101461850B (en) | Application of Chinese medicinal composition in preparing medicament for treating acne | |
| CN101810666B (en) | Veterinary synergic enrofloxacin injection and preparation method thereof | |
| CN105770859A (en) | Liquid medicine for treating acnes | |
| CN108743697A (en) | A kind of application of littleleaf indianmulberry root and stem extract in treating acute viral pharyngitis | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| AU2021104085A4 (en) | Hpv-resistant lactic acid bacteria gynecological preparation and application thereof | |
| CN101066410B (en) | Chinese medicine preparation for treating women's chronic pelvic inflammation and its preparation process | |
| CN101411757B (en) | Injection for treating milk cattle mastitis and preparation method thereof | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing Hongtai Kangda Pharmaceutical Technology Co., Ltd. Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110608 Termination date: 20171107 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |